DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.28
+0.39 (6.62%)
At close: Jun 23, 2026, 4:00 PM EDT
6.43
+0.15 (2.39%)
After-hours: Jun 23, 2026, 7:53 PM EDT
DiaMedica Therapeutics Employees
DiaMedica Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 7 or 25.00% compared to the previous year.
Employees
35
Change (1Y)
7
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,002,886
Market Cap
338.39M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 7 | 25.00% | 35 | 0 |
| Dec 31, 2024 | 28 | 9 | 47.37% | 27 | 1 |
| Dec 31, 2023 | 19 | 3 | 18.75% | 18 | 1 |
| Dec 31, 2022 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2021 | 15 | 4 | 36.36% | 14 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsDMAC News
- 10 hours ago - DiaMedica Therapeutics announces dosing of first two patients in DM199 study - TheFly
- 14 hours ago - DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire
- 7 days ago - DiaMedica Therapeutics receives written response from FDA on DM199 - TheFly
- 7 days ago - DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program - Business Wire
- 21 days ago - DiaMedica Therapeutics Slides: Corporate presentation - Filings
- 27 days ago - DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 - Business Wire
- 4 weeks ago - DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial - TheFly
- 4 weeks ago - DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire